176 related articles for article (PubMed ID: 24588075)
21. Methotrexate-induced liver cirrhosis in a patient of psoriasis.
Avasthi G; Bhatt P; Singh J
J Assoc Physicians India; 2012 May; 60():47-8. PubMed ID: 23029724
[TBL] [Abstract][Full Text] [Related]
22. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis.
Chalmers RJ; Kirby B; Smith A; Burrows P; Little R; Horan M; Hextall JM; Smith CH; Klaber M; Rogers S
Br J Dermatol; 2005 Mar; 152(3):444-50. PubMed ID: 15787812
[TBL] [Abstract][Full Text] [Related]
23. Comparison of noninvasive screening tools for hepatic fibrosis, association with methotrexate cumulative dose, and risk factors in psoriasis patients.
Lee JHM; Loo CH; Tan WC; Lee CK; Jamil A; Khor YH
Dermatol Ther; 2022 Jan; 35(1):e15203. PubMed ID: 34779102
[TBL] [Abstract][Full Text] [Related]
24. Liver fibrosis screening for patients with psoriasis taking methotrexate: a cross-sectional study comparing transient elastography and liver biopsy.
Bray AP; Barnova I; Przemioslo R; Kennedy CT
Br J Dermatol; 2012 May; 166(5):1125-7. PubMed ID: 21967341
[No Abstract] [Full Text] [Related]
25. Methotrexate and liver function: a study of 13 psoriasis cases treated with different cumulative dosages.
Carneiro SC; Cássia FF; Lamy F; Chagas VL; Ramos-e-Silva M
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):25-9. PubMed ID: 18181969
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis of liver fibrosis by transient elastography (FibroScan) and non-invasive methods in Crohn's disease patients treated with methotrexate.
Laharie D; Zerbib F; Adhoute X; Boué-Lahorgue X; Foucher J; Castéra L; Rullier A; Bertet J; Couzigou P; Amouretti M; de Lédinghen V
Aliment Pharmacol Ther; 2006 Jun; 23(11):1621-8. PubMed ID: 16696812
[TBL] [Abstract][Full Text] [Related]
27. Metabolic syndrome and female gender, but not methotrexate, are the important associations of significant liver fibrosis in patients with moderate-to-severe psoriasis as detected by transient elastography.
Mahajan R; Dogra S; Handa S; Razmi TM; Narang T; Rathi S; Dhiman RK; Saikia B; Karim A
Indian J Dermatol Venereol Leprol; 2020; 86(6):649-655. PubMed ID: 32643632
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies--a further 10-year follow-up.
Zachariae H; Søgaard H; Heickendorff L
Dermatology; 1996; 192(4):343-6. PubMed ID: 8864370
[TBL] [Abstract][Full Text] [Related]
29. Comparative tolerability of systemic treatments for plaque-type psoriasis.
McClure SL; Valentine J; Gordon KB
Drug Saf; 2002; 25(13):913-27. PubMed ID: 12381213
[TBL] [Abstract][Full Text] [Related]
30. Complications in methotrexate treatment of psoriasis with particular reference to liver fibrosis.
Ashton RE; Millward-Sadler GH; White JE
J Invest Dermatol; 1982 Oct; 79(4):229-32. PubMed ID: 7130740
[TBL] [Abstract][Full Text] [Related]
31. [Serum liver tests in patients treated with methotrexate. A retrospective analysis].
Correa G H; Paredes S N
Rev Med Chil; 2007 Aug; 135(8):1002-8. PubMed ID: 17989857
[TBL] [Abstract][Full Text] [Related]
32. Galactose tolerance test and methotrexate-induced liver fibrosis and cirrhosis in patients with psoriasis.
Lenler-Petersen P; Søgård H; Thestrup-Pedersen K; Zachariae H
Acta Derm Venereol; 1982; 62(5):448-9. PubMed ID: 6183903
[TBL] [Abstract][Full Text] [Related]
33. The acitretin and methotrexate combination therapy for psoriasis vulgaris achieves higher effectiveness and less liver fibrosis.
An J; Zhang D; Wu J; Li J; Teng X; Gao X; Li R; Wang X; Xia L; Xia Y
Pharmacol Res; 2017 Jul; 121():158-168. PubMed ID: 28414177
[TBL] [Abstract][Full Text] [Related]
34. Biomarkers for methotrexate-induced liver injury: urinary protein profiling of psoriasis patients.
van Swelm RP; Laarakkers CM; Kooijmans-Otero M; de Jong EM; Masereeuw R; Russel FG
Toxicol Lett; 2013 Aug; 221(3):219-24. PubMed ID: 23830989
[TBL] [Abstract][Full Text] [Related]
35. Comment on: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy.
Boffa MJ; Smith A; Chalmers RJ
Rheumatology (Oxford); 2009 Nov; 48(11):1464; author reply 1465. PubMed ID: 19671697
[No Abstract] [Full Text] [Related]
36. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients.
Boffa MJ; Smith A; Chalmers RJ; Mitchell DM; Rowan B; Warnes TW; Shomaf M; Haboubi NY
Br J Dermatol; 1996 Oct; 135(4):538-44. PubMed ID: 8915142
[TBL] [Abstract][Full Text] [Related]
37. Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury.
Langman G; Hall PM; Todd G
J Gastroenterol Hepatol; 2001 Dec; 16(12):1395-401. PubMed ID: 11851839
[TBL] [Abstract][Full Text] [Related]
38. A liver fibrosis cocktail? Psoriasis, methotrexate and genetic hemochromatosis.
Mathew J; Leong MY; Morley N; Burt AD
BMC Dermatol; 2005 Nov; 5():12. PubMed ID: 16316460
[TBL] [Abstract][Full Text] [Related]
39. Methotrexate hepatotoxicity: what is the evidence?
Ahern MJ; Smith MD; Roberts-Thomson PJ
Inflamm Res; 1998 Apr; 47(4):148-51. PubMed ID: 9628257
[No Abstract] [Full Text] [Related]
40. The quest for an evidence-based approach to surveillance for methotrexate-related hepatotoxicity: promise and perils.
Dawwas MF; Aithal GP
Br J Dermatol; 2015 Jun; 172(6):1684-1685. PubMed ID: 25523838
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
